inVentiv Health Creates Industry’s Largest Global Network of Medical Communications Experts with Expansion Into Tokyo and New York City
inVentiv Medical Communications Adds Significantly to Its International Team of Scientists, PhDs and Experts Delivering Sophisticated Peer-to-Peer Communications
BURLINGTON, Mass., – July 29, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced that its medical communications business has opened two new offices in Tokyo and New York creating the industry’s largest global network of experts in peer-to-peer medical and scientific communications.
In opening the two new offices, inVentiv Medical Communications (iMC) dramatically expands its existing team of 180 scientists, writers, communications experts and PhD’s in offices across North America, Europe and Asia. iMC has been expanding its global footprint in response to client demand for its unique expertise, and already has offices in London, Munich, Paris, Shanghai, Dallas and the Philadelphia area.
iMC understands healthcare professionals and health systems throughout the world, so can offer clients both a global perspective and local insights. The result is rich, persuasive communications that educate and influence the clinical and payer audiences the healthcare industry must reach for successful commercialization.
iMC is uniquely focused on facilitating peer-to-peer and scientific communications. Its use of a full range of communications channels is bolstered by employing cutting-edge digital technology. Working in close partnership with clients, iMC provides medical strategies for Advisory Boards, medical content development and publication, virtual and in-person events and communications between physicians, nurses and healthcare professionals. The goal is to build relationships, foster understanding and encourage collaboration between the biopharmaceutical industry and medical/healthcare professionals.
“inVentiv Medical Communications bridges the gap between clinical trials and the commercialization of a product,” said Paul Meister, CEO of inVentiv Health. “This type of sophisticated support has never been more important in facilitating access to products because market access today is about more than just the cost of a drug.
“Access means ensuring that clinicians prescribing a drug or using a device have the data they need, are up-to-date regarding the disease or condition being treated, know why a product works and understand how to derive maximum benefit for patients. That’s why more and more clients are turning to the experts at iMC for support.”
Nearly all iMC personnel hold PhD’s or other advanced degrees. The team includes oncologists, hematologists, neuroscientists, biologists, pharmacists, medical writers, program managers, strategists and specialists in market access.
“With this level of expertise, we are able to help clients influence change within clinical and payer audiences,” said Elaine Ferguson, Global Managing Director of iMC. “Now, with these new offices, we are everywhere our clients need us to be, providing scientific rigor and value- based communications solutions that are the best in the business.”
The new staff members in New York City were formerly part of Noveida Health. John LaPolla, who will lead the New York team, holds degrees in microbiology from Cornell University and in biochemistry from Mount Sinai Medical Center. For 14 years, he has specialized in oncology and chronic pain, as well as cardiometabolic and psychiatric disorders. He has been an innovator in market access and has developed cutting-edge technology platforms for some of the world’s largest pharmaceutical companies, as well as for biotech startups.
In Tokyo, iMC will be led by Aya Tokaji as Director of Scientific Services. The Tokyo team will work alongside iMC’s China office which earlier this month won a contract to provide a global pharmaceutical client with assistance in understanding China’s oncology landscape and support at an upcoming medical meeting on oncology.
iMC has the unique ability to tap into and integrate an extensive range of creative capabilities across all of inVentiv Health, including public relations, advertising and marketing, as well as clinical trial, outsourced sales, risk mitigation, compliance and broad patient support expertise.
“At inVentiv, medical communications isn’t an afterthought as it is at other communications firms. Rather, it is absolutely integral, a core capability and built into everything we do,” Ferguson said. “For companies wanting to accelerate time to market, the sophisticated medical communications we can provide has become mission critical.”
About inVentiv Health Communications
inVentiv Health Communications (iHC) is the inVentiv Health division dedicated to delivering exceptional, global, multichannel communications to organizations focused on health and wellness. The company’s unified offer brings together inVentiv Health’s advertising, public relations, public policy, market access, medical communications, media, creative, branding and digital services creating a “Super Agency” structure. iHC provides relevant, targeted and flexible marketing solutions for the pharmaceutical industry and organizations with a healthcare focus, enabling clients to excel in a rapidly changing environment.
About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.